OVERVIEW
An argument that the two anti-HER2 agents, trastuzumab and lapatinib, given together would be better than single-agent therapy.
STUDY DETAILS
The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
Title of publication
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
AUTHORS
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T-W., Horváth, Z., Coccia-Portugal, M., Domont, J., Tseng, L-M., Kunz, G., Sohn, J.H., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, R.D., and Piccart-Gebhart, M. on behalf of the NeoALTTO Study Team
PUBLICATION REFERENCE
The Lancet | Volume 379 | Issue 9816 | Page(s) 633-640 | 2012
